Eversept Partners, L.P. 13F annual report
Eversept Partners, L.P. is an investment fund managing more than $1.31 trillion ran by Ron Rosenstraus. There are currently 72 companies in Mr. Rosenstraus’s portfolio. The largest investments include GSK Plc and Natera Inc, together worth $261 billion.
$1.31 trillion Assets Under Management (AUM)
As of 7th August 2024, Eversept Partners, L.P.’s top holding is 3,468,080 shares of GSK Plc currently worth over $134 billion and making up 10.2% of the portfolio value.
Relative to the number of outstanding shares of GSK Plc, Eversept Partners, L.P. owns more than approximately 0.1% of the company.
In addition, the fund holds 1,173,494 shares of Natera Inc worth $127 billion, whose value grew 65.4% in the past six months.
The third-largest holding is Insmed Inc worth $77.4 billion and the next is Teva Pharmaceutical Inds Ltd worth $76.7 billion, with 4,720,460 shares owned.
Currently, Eversept Partners, L.P.'s portfolio is worth at least $1.31 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Eversept Partners, L.P.
The Eversept Partners, L.P. office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Ron Rosenstraus serves as the Chief Financial Officer at Eversept Partners, L.P..
Recent trades
In the most recent 13F filing, Eversept Partners, L.P. revealed that it had opened a new position in
Insmed Inc and bought 1,155,588 shares worth $77.4 billion.
This means they effectively own approximately 0.1% of the company.
Insmed Inc makes up
8.5%
of the fund's Health Care sector allocation and has grown its share price by 242.5% in the past year.
The investment fund also strengthened its position in Syndax Pharmaceuticals Inc by buying
480,518 additional shares.
This makes their stake in Syndax Pharmaceuticals Inc total 3,613,631 shares worth $74.2 billion.
Syndax Pharmaceuticals Inc soared 5.4% in the past year.
On the other hand, there are companies that Eversept Partners, L.P. is getting rid of from its portfolio.
Eversept Partners, L.P. closed its position in Pfizer on 14th August 2024.
It sold the previously owned 1,102,042 shares for $30.6 billion.
Ron Rosenstraus also disclosed a decreased stake in GSK Plc by approximately 0.1%.
This leaves the value of the investment at $134 billion and 3,468,080 shares.
One of the largest hedge funds
The two most similar investment funds to Eversept Partners, L.P. are Jordan Park and Cerity Partners Ocio. They manage $1.31 trillion and $1.31 trillion respectively.
Ron Rosenstraus investment strategy
Eversept Partners, L.P.’s portfolio is diversified across 3 sectors.
Currently, their heaviest sector is Health Care — making up 69.7% of
the total portfolio value.
The fund focuses on investments in the United States as
58.3% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
18% of the total holdings value.
On the other hand, small-cap stocks make up only 1.4% of the portfolio.
The average market cap of the portfolio companies is close to $13.3 billion.
The complete list of Eversept Partners, L.P. trades based on 13F SEC filings
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| GSK Plc |
8.06%
3,468,080
|
$133,521,080,000 | 10.22% |
| Natera Inc |
34.00%
1,173,494
|
$127,077,665,000 | 9.73% |
| Insmed Inc |
Opened
1,155,588
|
$77,424,396,000 | 5.93% |
| Teva Pharmaceutical Inds Ltd |
21.65%
4,720,460
|
$76,707,475,000 | 5.87% |
| United Therapeutics Corp |
6.29%
235,351
|
$74,971,061,000 | 5.74% |
| Syndax Pharmaceuticals Inc |
15.34%
3,613,631
|
$74,187,844,000 | 5.68% |
| Vera Therapeutics Inc |
12.03%
2,043,214
|
$73,923,483,000 | 5.66% |
| Inspire Med Sys Inc |
26.70%
533,011
|
$71,332,862,000 | 5.46% |
| Revvity Inc. |
6.54%
451,582
|
$47,352,889,000 | 3.62% |
| HCA Healthcare Inc |
30.49%
135,480
|
$43,527,014,000 | 3.33% |
| Bio-Techne Corp |
10.64%
543,044
|
$38,909,103,000 | 2.98% |
| Healthequity Inc |
1.85%
413,531
|
$35,646,372,000 | 2.73% |
| Pfizer Inc. |
Closed
1,102,042
|
$30,581,666,000 | |
| Community Health Sys Inc New |
0.71%
8,037,470
|
$27,005,899,000 | 2.07% |
| Shockwave Med Inc |
Closed
80,555
|
$26,231,125,000 | |
| Repligen Corp. |
2,258.76%
194,291
|
$24,492,323,000 | 1.87% |
| Celldex Therapeutics Inc. |
10.98%
633,015
|
$23,427,885,000 | 1.79% |
| Ionis Pharmaceuticals Inc |
21.37%
456,881
|
$21,774,948,000 | 1.67% |
| Novo-nordisk A S |
135.72%
146,956
|
$20,976,499,000 | 1.61% |
| Eli Lilly Co |
64.89%
21,233
|
$19,223,934,000 | 1.47% |
| Tenet Healthcare Corp. |
Closed
175,631
|
$18,460,574,000 | |
| Protagonist Therapeutics Inc |
22.93%
505,836
|
$17,527,217,000 | 1.34% |
| Argenx Se |
36.55%
34,593
|
$14,876,374,000 | 1.14% |
| Humana Inc. |
7.01%
38,023
|
$14,207,294,000 | 1.09% |
| Viatris Inc. |
0.97%
1,329,282
|
$14,130,268,000 | 1.08% |
| Zimvie Inc |
35.99%
767,659
|
$14,009,777,000 | 1.07% |
| Mannkind Corp |
5.61%
2,256,952
|
$11,781,289,000 | 0.90% |
| Taro Pharmaceutical Inds Ltd |
Closed
263,541
|
$11,158,326,000 | |
| Brookdale Sr Living Inc |
17.29%
1,546,842
|
$10,564,931,000 | 0.81% |
| Danaher Corp. |
No change
40,855
|
$10,207,622,000 | 0.78% |
| Spdr Ser Tr |
Opened
100,000
|
$9,271,000,000 | 0.71% |
| Travere Therapeutics Inc |
14.18%
1,091,165
|
$8,969,376,000 | 0.69% |
| Elevance Health Inc |
1.83%
14,657
|
$7,942,042,000 | 0.61% |
| Arcutis Biotherapeutics Inc |
Opened
837,847
|
$7,791,977,000 | 0.60% |
| Centene Corp. |
24.82%
115,820
|
$7,678,866,000 | 0.59% |
| Viridian Therapeutics Inc |
299.43%
567,487
|
$7,383,006,000 | 0.57% |
| Viking Therapeutics Inc |
506.93%
138,489
|
$7,341,302,000 | 0.56% |
| Vaxcyte, Inc. |
51.31%
96,089
|
$7,255,680,000 | 0.56% |
| Biocryst Pharmaceuticals Inc. |
19.54%
1,152,573
|
$7,122,901,000 | 0.55% |
| Cytokinetics Inc |
Opened
126,877
|
$6,874,196,000 | 0.53% |
| Taysha Gene Therapies, Inc. |
Closed
2,325,591
|
$6,674,446,000 | |
| Newamsterdam Pharma Company |
6.80%
329,890
|
$6,337,187,000 | 0.48% |
| Evolus Inc |
Opened
574,462
|
$6,232,913,000 | 0.48% |
| Molina Healthcare Inc |
213.61%
18,277
|
$5,433,752,000 | 0.42% |
| Sutro Biopharma Inc |
59.35%
1,739,129
|
$5,095,648,000 | 0.39% |
| Gossamer Bio, Inc. |
8.51%
5,484,148
|
$4,940,669,000 | 0.38% |
| Oscar Health, Inc. |
Opened
310,893
|
$4,918,327,000 | 0.38% |
| Waters Corp. |
Closed
13,628
|
$4,691,166,000 | |
| Cerevel Therapeutics Hldng I |
Opened
110,010
|
$4,498,309,000 | 0.34% |
| Liquidia Corp |
5.71%
373,554
|
$4,482,648,000 | 0.34% |
| Myriad Genetics, Inc. |
Opened
181,961
|
$4,450,766,000 | 0.34% |
| Puma Biotechnology Inc |
6.87%
1,328,454
|
$4,330,760,000 | 0.33% |
| Karyopharm Therapeutics Inc |
0.58%
4,987,180
|
$4,326,877,000 | 0.33% |
| 2seventy Bio Inc |
5.94%
1,107,743
|
$4,264,811,000 | 0.33% |
| Nevro Corp |
28.16%
499,395
|
$4,204,906,000 | 0.32% |
| Icon Plc |
17.63%
12,642
|
$3,962,888,000 | 0.30% |
| Merus N.V |
44.36%
66,474
|
$3,933,267,000 | 0.30% |
| Corbus Pharmaceuticals Hldgs |
Closed
88,934
|
$3,489,770,000 | |
| Krystal Biotech Inc |
Closed
18,557
|
$3,301,847,000 | |
| Moonlake Immunotherapeutics |
Opened
71,596
|
$3,148,076,000 | 0.24% |
| Morphosys AG |
Closed
165,924
|
$3,009,861,000 | |
| Amarin Corp Plc |
30.65%
4,308,527
|
$2,964,267,000 | 0.23% |
| Guardant Health Inc |
77.90%
99,377
|
$2,870,008,000 | 0.22% |
| Inflarx Nv |
20.06%
1,566,930
|
$2,726,458,000 | 0.21% |
| Avantor, Inc. |
No change
125,394
|
$2,658,353,000 | 0.20% |
| Tourmaline Bio Inc |
Opened
204,781
|
$2,633,484,000 | 0.20% |
| IQVIA Holdings Inc |
No change
12,178
|
$2,574,916,000 | 0.20% |
| Alector, Inc. |
1.04%
541,739
|
$2,459,495,000 | 0.19% |
| Immunovant Inc |
63.64%
92,909
|
$2,452,798,000 | 0.19% |
| Xoma Corp Del |
5.31%
91,907
|
$2,177,277,000 | 0.17% |
| Autolus Therapeutics plc |
Opened
610,902
|
$2,125,939,000 | 0.16% |
| Terns Pharmaceuticals Inc |
1.14%
286,266
|
$1,949,471,000 | 0.15% |
| Mereo BioPharma Group plc |
Opened
496,171
|
$1,786,216,000 | 0.14% |
| Aerovate Therapeutics Inc |
Closed
54,150
|
$1,601,216,000 | |
| Curevac N V |
Closed
515,691
|
$1,562,544,000 | |
| Kura Oncology Inc |
Opened
72,317
|
$1,489,007,000 | 0.11% |
| Absci Corporation |
Opened
325,509
|
$1,002,568,000 | 0.08% |
| Fulcrum Therapeutics Inc |
Opened
152,965
|
$948,383,000 | 0.07% |
| Affimed N.V. |
No change
166,460
|
$907,207,000 | 0.07% |
| Stoke Therapeutics, Inc. |
78.87%
61,277
|
$827,852,000 | 0.06% |
| G1 Therapeutics Inc |
Opened
199,963
|
$455,916,000 | 0.03% |
| Vincerx Pharma Inc |
Closed
79,588
|
$402,715,000 | |
| AC Immune SA |
20.29%
99,313
|
$396,259,000 | 0.03% |
| Seres Therapeutics Inc |
69.89%
418,208
|
$302,699,000 | 0.02% |
| No transactions found | |||
| Showing first 500 out of 84 holdings | |||
Hedge funds similar to Eversept Partners, L.P.
- Sprott Inc
- Portolan Capital Management
- Greenvale Capital LL.P.
- London & Capital Asset Management Ltd
- Aventail Capital L.P.
- Easterly Investment Partners
- Principle Wealth Partners
- Jordan Park
- Cerity Partners Ocio
- Sandhill Capital Partners
- Gam Ag
- Cidel Asset Management Inc
- North Star Investment Management
- Fukoku Mutual Life Insurance Co